Proxima Clinical Research Named 2021 Best Place to Work by Modern Healthcare
Only 150 companies from across the U.S. receive this prestigious honor each year
Houston, May 20, 2021 – Proxima Clinical Research (“Proxima CRO”) has been named by Modern Healthcare as one of the 2021 Best Places to Work in Healthcare. Proxima CRO is a next generation contract research organization (CRO) based out of the Texas Medical Center in Houston.
“We are excited and honored to make this list,” says Kevin Coker, CEO. “This is a competitive process based on employee feedback, not an application. Only the best companies, as designated by their employees, receive this designation. The credit goes to our team for owning our culture and being a part of its continued development.”
The program identifies and recognizes only 150 outstanding employers nationwide from across the healthcare industry. Only 3-1/2 years in business, Proxima is honored to be included in the prestigious list together with larger brands such as HCA, Blue Cross Blue Shield, and Memorial Healthcare. Modern Healthcare partners with Best Companies Group on the assessment process, which includes an extensive employee survey with anonymous feedback.
“We strive to create a highly communicative culture where we are solving problems together. This Best Place to Work recognition is validation that we’re on the right path,” says Coker. “The recent surge in medical device and biotech innovation led to quick growth in our company over the last 10 months. I feel we are doing great things and it’s great to learn, through third party validation, that the team feels the same way.”
A complete list of winners is available at ModernHealthcare.com/bestplaceslist. Official rankings will be announced Sept. 16 in Chicago at the Best Places to Work Gala. A special insert in the September 20th issue of Modern Health will list the official rankings.
In addition to this recognition, Proxima CRO has earned certification from Great Place to Work®, a global authority on workplace culture. Proxima recently announced tremendous growth, having doubled its clients, and tripled its staff and trials. Growth projections remain strong in 2021 and 2022.